MWA
CRSP icon

Medallion Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Medallion Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.8K Hold
88
– – ﹤0.01% 864
2026
Q1 		$4.19K Hold
88
– – ﹤0.01% 910
2025
Q4 		$4.62K Sell
88
-36
-29% -$2.16K ﹤0.01% 871
2025
Q3 		$8.04K Hold
124
– – ﹤0.01% 786
2025
Q2 		$6.01K Hold
124
– – ﹤0.01% 806
2025
Q1 		$4.11K Hold
124
– – ﹤0.01% 821
2024
Q4 		$4.88K Buy
+124
New +$5.86K ﹤0.01% 750

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Medallion Wealth Advisors's CRSP Position: Q2 2026 in Review

Medallion Wealth Advisors held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 88 shares worth $4.8K. The position accounts for ﹤0.01% of the portfolio, ranked #864.

Medallion Wealth Advisors first reported a position in CRSP in Q4 2024 and has held it in 7 quarters since. The position peaked at $8.04K in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Medallion Wealth Advisors held 88 shares of CRISPR Therapeutics worth $4.8K as of Q2 2026.
  • Medallion Wealth Advisors left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Medallion Wealth Advisors's portfolio in Q2 2026, its #864 holding.
  • Medallion Wealth Advisors first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Medallion Wealth Advisors's CRISPR Therapeutics position peaked at $8.04K in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Medallion Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.